Ipilimumab and Nivolumab for Treatment of Eyelid Spindle Cell Melanoma

Am J Ophthalmol. 2023 Jun:250:e1-e2. doi: 10.1016/j.ajo.2023.02.010. Epub 2023 Feb 18.

Authors

Marissa K Shoji¹, Andrew J Rong²

Affiliations

¹ Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, FL. Electronic address: mshojimd@gmail.com.
² Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, FL. Electronic address: ajr211@med.miami.edu.

PMID: 36801380
DOI: 10.1016/j.ajo.2023.02.010

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Humans
Ipilimumab / therapeutic use
Melanoma* / drug therapy
Nivolumab / therapeutic use
Skin Neoplasms* / drug therapy

Substances

Nivolumab
Ipilimumab
Antibodies, Monoclonal